| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NBIX | Common Stock | Sale | -$170K | -1.21K | -3.11% | $140.78 | 37.6K | Jan 31, 2024 | Direct | F1, F2, F3 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Sale of 1,207 shares of common stock issued upon vesting of 2,294 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (1,087) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. |
| F2 | Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.68 to $142.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| F3 | Includes an aggregate of 78 shares purchased on August 31, 2023 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |